Farzin Tahmasbi Arashlow

Dr. Farzin Tahmasbi Arashlow

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SSShayan Shojaei
Shayan Shojaei
AMAsma Mousavi
Asma Mousavi
SKSina Kazemian
Sina Kazemian
SMShiva Armani moghadam
Shiva Armani moghadam
SMSaba Maleki
Saba Maleki
KHKaveh Hosseini
Kaveh Hosseini
Background/Objectives: Transcatheter aortic valve replacement (TAVR) has been introduced as an optimal treatment for patients with severe aortic stenosis, offering a minimally invasive alternative to surgical aortic valve replacement. Predicting these outcomes following TAVR is crucial. Artificial intelligence (AI) has emerged as a promising tool for improving post-TAVR outcome prediction. In this systematic review and meta-analysis, we aim to summarize the current evidence on utilizing AI in predicting post-TAVR outcomes. Methods: A comprehensive search was conducted to evaluate the studies focused on TAVR that applied AI methods for risk stratification. We assessed various ML algorithms, including random forests, neural networks, extreme gradient boosting, and support vector machines. Model performance metrics—recall, area under the curve (AUC), and accuracy—were collected with 95% confidence intervals (CIs). A random-effects meta-analysis was conducted to pool effect estimates. Results: We included 43 studies evaluating 366,269 patients (mean age 80 ± 8.25; 52.9% men) following TAVR. Meta-analyses for AI model performances demonstrated the following results: all-cause mortality (AUC = 0.78 (0.74–0.82), accuracy = 0.81 (0.69–0.89), and recall = 0.90 (0.70–0.97); permanent pacemaker implantation or new left bundle branch block (AUC = 0.75 (0.68–0.82), accuracy = 0.73 (0.59–0.84), and recall = 0.87 (0.50–0.98)); valve-related dysfunction (AUC = 0.73 (0.62–0.84), accuracy = 0.79 (0.57–0.91), and recall = 0.54 (0.26–0.80)); and major adverse cardiovascular events (AUC = 0.79 (0.67–0.92)). Subgroup analyses based on the model development approaches indicated that models incorporating baseline clinical data, imaging, and biomarker information enhanced predictive performance. Conclusions: AI-based risk prediction for TAVR complications has demonstrated promising performance. However, it is necessary to evaluate the efficiency of the aforementioned models in external validation datasets.


21 May 2026 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
NSNiloofar Seighali
Niloofar Seighali
MGMohammad Sadra Gholami-Chahkand
Mohammad Sadra Gholami-Chahkand
MEMandana Ebrahimzade
Mandana Ebrahimzade
FAFarzin Tahmasbi Arashlow
Farzin Tahmasbi Arashlow
SMSeyede Parmis Maroufi
Seyede Parmis Maroufi
KHKaveh Hosseini
Kaveh Hosseini
Obesity is linked to cardiometabolic risk, and semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising option for weight and me

13 November 2024 in Clinical Epidemiology and Global Health
Verified
Journal Article
Open access
SMSeyed Ehsan Mousavi
Seyed Ehsan Mousavi
KAKimia Motlagh Asghari
Kimia Motlagh Asghari
AAArmin Aslani
Armin Aslani
FAFarzin Tahmasbi Arashlow
Farzin Tahmasbi Arashlow
ZYZahra Yekta
Zahra Yekta
SNSeyed Aria Nejadghaderi
Seyed Aria Nejadghaderi